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Essentials
• Current risk scores for heparin-induced thrombocytopenia (HIT) are not computer-friendly.
• We compared a new computerized risk score with the 4Ts score in a large healthcare system. • The computerized risk score agrees with the 4Ts score 85% of the time.
• The new score could potentially improve HIT diagnosis via incorporation into decision support.
Summary. Background: (HIT) is an immune-mediated adverse drug event associated with life-threatening thrombotic complications. The 4Ts score is widely used to estimate the risk for HIT and guide diagnostic testing, but it is not easily amenable to computerized clinical decision support (CDS) implementation. Objectives: Our main objective was to develop an HIT computerized risk (HIT-CR) scoring system that provides platelet count surveillance for timing and degree of thrombocytopenia to identify those for whom diagnostic testing should be considered. Our secondary objective was to evaluate clinical management and subsequent outcomes in those identified as being at risk for HIT. Methods:
We retrospectively analyzed data from a stratified sample of 150 inpatients treated with heparin to compare the performance of the HIT-CR scoring system with that of a clinically calculated 4Ts score. We took a 4Ts score of ≥ 4 as the gold standard to determine whether HIT diagnostic testing should be performed. Results:
The best cutoff point of the HIT-CR score was a score of 3, which yielded 85% raw agreement with the 4Ts score and a kappa of 0.69 (95% confidence interval 0.57-0.81). Ninety per cent of patients with 4Ts score of ≥ 4 failed to undergo conventionally recommended diagnostic testing; 38% of these experienced persistent, unexplained thrombocytopenia, and 4% suffered life-threatening thrombotic complications suggestive of undiagnosed HIT. Conclusion: The HIT-CR scoring system is practical for computerized CDS, agrees well with the 4Ts score, and should be prospec
Introduction
Heparin-induced thrombocytopenia (HIT) is a clinicalpathological syndrome characterized by thrombocytopenia and thrombotic complications associated with the formation of anti-platelet factor 4/heparin (anti-PF4/H) antibodies, typically occurring within 5-10 days of exposure to heparin [1] . The unpredictable nature of HIT and the associated mortality make it a significant patient safety issue. The epidemiological and clinical characteristics of HIT make it particularly important, but difficult, to diagnose in a timely manner. Thrombocytopenia is common in hospitalized patients, and HIT is rarely the cause [2] . Although approximately one-third of hospitalized patients (12 million patients per year in the USA) receive heparin or low molecular weight heparin (LMWH), only about 0.2% of heparin-exposed patients are diagnosed with HIT [3] . A recent analysis of a cohort of 465 hospitalized patients experiencing thrombocytopenia showed that 2.2% were tested for HIT, all with negative test results [2] .
Although data are not available on how often the diagnosis of HIT is missed, most clinicians have limited experience with the condition, potentially decreasing their clinical vigilance and recognition of HIT in its earliest stages. Delayed recognition of HIT can result in death from thrombotic complications, including deep vein thrombosis, venous limb gangrene, pulmonary embolism, and stroke. Thrombosis occurs rapidly after the development of thrombocytopenia in about 50% of patients with HIT, resulting in mortality rate of approximately 10-15% [4, 5] . Conversely, indiscriminant laboratory testing of patients with a low pretest probability for HIT significantly increases the number of false-positive immunoassay results, leading to unnecessary use of alternative, more expensive antithrombotic agents with an increased risk of severe bleeding complications [6, 7] . A clinical decision support (CDS) tool that assists clinicians in recognizing that a hospitalized patient may be experiencing early manifestations of HIT and should undergo diagnostic testing and presumptive therapy for HIT would therefore be of significant benefit.
The 4Ts score is a widely used pretest HIT risk assessment tool that uses clinical and laboratory data to riskstratify patients with suspected HIT and to determine which patients warrant specific diagnostic testing [8, 9] . The 4Ts score incorporates: (i) the thrombocytopenia magnitude; (ii) the timing of the onset of thrombocytopenia in relation to initiation of heparin; (iii) the occurrence of subsequent thrombotic complications; and (iv) the presence/absence of other causes of thrombocytopenia. Each component is scored on a 0-2 scale, and the points are summed. Patients with a 4Ts score of 0-3 are considered to have a low risk for HIT (< 2%), and therefore [10, 11] should not routinely undergo diagnostic testing. Patients with intermediate (4) (5) and high (6) (7) (8) scores have a 14% chance and 64% chance of developing HIT, respectively, and are considered to require immediate discontinuation of heparin and presumptive alternative antithrombotic therapy pending the results of diagnostic testing for anti-PF4/H antibodies.
However, the 4Ts score has important practical limitations. Clinicians may not immediately and reliably recognize thrombocytopenia as an early manifestation of HIT, delaying the consideration of 4Ts scoring. The criteria used to determine the 4Ts score are not entirely objective, and inter-rater reliability (kappa score) as poor as 0.3 has been reported [12] . Not all clinicians choose to use the 4Ts score once they suspect the diagnosis of HIT, and unassisted calculation of the score can be time-consuming.
We sought to develop a CDS tool that would provide reliable surveillance of the electronic medical record (EMR) for patients receiving heparin in order to alert clinicians to the earliest manifestations of HIT and assist them in making an evidence-based decision on whether or not the patient should undergo presumptive treatment and diagnostic testing for HIT. Unfortunately, the 4Ts score is not amenable to straightforward automated calculation, as the third and fourth scoring criteria are not discrete data elements in the EMR and are difficult to extract, even for EMRs with some natural language-processing capability. The first and second 4Ts scoring criteria are more amenable to EMR abstraction, but variability in interpretation of the second criterion (thrombocytopenia onset) has yielded suboptimal interrater agreement, and would require standardization prior to automated calculation [13, 14] .
Therefore, we developed a simplified, computer-based risk scoring tool derived from the first two domains of the 4Ts score -the magnitude of thrombocytopenia, and the timing of thrombocytopenia onset in relation to the initiation of heparin -which we call the HIT computerized risk (HIT-CR) score. The primary aim of our study was to determine the discriminant accuracy and optimal cutoff for the HIT-CR score in identifying patients for whom HIT diagnostic testing is recommended (patients with a 4Ts score ≥ 4) and to quantify the agreement between the HIT-CR and 4Ts scores. Our secondary aim was to evaluate the clinical outcomes of patients retrospectively discovered to have a 4Ts score of ≥ 4 (intermediate to high risk of HIT) who failed to undergo recommended diagnostic testing for HIT, to determine whether we could identify potential missed cases of HIT.
Methods
This retrospective study is the first phase of a continuous quality improvement study conducted in a large healthcare system of 28 hospitals in six states in the western USA. This study was granted exemption from Institutional Review Board approval by our institution's Research Determination Committee. We developed computerized decision-support logic within the CERNER MIL-LENNIUM (Cerner Corp., Kansas City, MO, USA) EMR by using DISCERN EXPERT to perform platelet count surveillance for all inpatients receiving unfractionated heparin or LMWH. This tool was used for investigative purposes only, and did not influence clinical care. Data were collected from 11 706 patient encounters in a 7-week period from July through September 2017. An order for heparin, enoxaparin or a cardiac surgery order set (because intraoperative heparin is often not explicitly ordered in the EMR of our healthcare system) triggered the decision support logic and logged the date/time of heparin initiation and highest platelet count within the last 24 h. All subsequent platelet counts for these active patients yielded an additional line of data including the date/time and platelet count for each patient.
Data were exported to Microsoft Excel, where scoring rules (Table 1) were applied to yield HIT-CR scores ranging from 0 to 4 for every resultant platelet count. Preliminary evaluation of this dataset showed that > 90% of patients had an HIT-CR score of zero. Therefore, we employed a disproportionate stratified sampling method to ensure that our final study selection included a sufficient number of higher-risk patients to enable the evaluation of different cutoff points.
We calculated that a sample size of 53 was needed to perform area under the receiver operating characteristic (ROC) curve (AUC) analysis comparing the HIT-CR score with a 4Ts score of ≥ 4 with 80% power, a twotailed alpha of 0.05, an anticipated allocation ratio of 0.5, and an expected AUC of 0.7. Owing to uncertainty in parameters such as the allocation ratio and AUC, we chose a sample size of 150 patients with equal allocation across the range of HIT-CR scores. All patients aged ≥ 18 years who received heparin or LMWH and experienced a decrease in platelet count of any magnitude within the first 20 days of admission were eligible for inclusion. All patients were eligible for selection regardless of length of stay or duration of heparin exposure. We used disproportionate stratified sampling and randomly selected patients from within each HIT-CR score group (possible scores include 0, 1, 2, 3, and 4). We analyzed the first occurrence of the relevant HIT-CR score, given that this is when a CDS advisory would be triggered.
The HIT-CR score for each patient was calculated according to the points system shown in in Table 1 . Time zero for each patient was established from the date/time when heparin was first administered or the time of surgery order set entry if the patient underwent cardiac surgery. The baseline platelet count was defined as the maximum platelet count from any sample collected from 24 h before time zero up until the time at which scoring was performed (that is, if an HIT-CR scored was obtained 7 days after heparin initiation, baseline would be the maximum platelet count occurring in the range of 24 h before heparin was started until day 7 after initiation). This definition of baseline platelet count will not always reflect the highest count immediately preceding the potential HIT-related platelet count fall, but was standardized for simplicity in the computer algorithm. The timing of the onset of platelet count fall was determined on the day that the platelet count reached a decrease of at least 30% from the baseline.
Next, two investigators (T.G. and A.P.) blinded to the HIT-CR scores independently conducted each chart review to determine 4Ts scores with reference to data clinically available on the day when the HIT-CR score was calculated, and were instructed not to view HIT diagnostic test results until after completion of 4Ts scoring. When discrepancies in 4Ts score HIT risk category (low versus intermediate/high) were encountered, a third physician investigator (R.R.) served as an adjudicator. After 4Ts scoring for a patient was complete, investigators collected age, gender, admission service, and details of any HIT diagnostic testing. Outcomes, including thrombotic events occurring subsequent to the onset of thrombocytopenia, were also extracted for all patients with 4Ts scores of ≥ 4.
AUC analysis was used to examine the discriminative accuracy of the HIT-CR score in identifying patients with a 4Ts score of ≥ 4 (those currently recommended to undergo diagnostic testing for HIT). The 95% confidence intervals (CIs) for the AUC were calculated with the DeLong method [15] . The optimal cutoff point for the HIT-CR scoring was determined by use of the point that minimized the distance between the ROC curve and the point (0,1), to balance sensitivity and specificity in comparison with the 4Ts score. Stratified likelihood ratios were calculated for each level of HIT-CR score. Cohen's kappa was calculated to determine the agreement accounting for chance between the HIT-CR score and the 4Ts score at the optimal cutoff point. A subgroup analysis was performed by calculating kappa in subgroups of surgical versus medical patients and unfractionated heparin versus LMWH. A kappa statistic was also calculated for the two independent investigators' determination of the 4Ts score. This calculation was based on a 4Ts score cutoff of ≥ 4 for a positive result, and was performed on the independently scored patients.
Results
The CDS logic yielded maximum HIT-CR scores of 0, 1, 2, 3 and 4, in 10 770, 379, 251, 245 and 61 patients, Decrease in platelets of < 30% or nadir of < 10 000 mm
À3
Timing of platelet count fall † 5-10 days Within 1 day or 10-20 days 2-4 days or > 20 days *Baseline for thrombocytopenia was defined as the highest platelet count in the time range of 24 h prior to heparin initiation/cardiac surgery up to the time at which scoring was performed. †Days after starting heparin.
respectively. One hundred and fifty hospitalized patients underwent chart review and were included in our analyses. Table 2 contains shows the data. The mean age was 62.5 years (standard deviation of 16.5 years), and there were 71 (47%) females. One hundred patients were admitted to the medical services, and 50 underwent surgery, including 19 cardiac and 10 orthopedic surgeries. Table 3 shows the proportion of patients in each category of HIT-CR score with a 4Ts score of ≥ 4. Overall, 100 patients were considered to be at low risk, 46 at intermediate risk, and four at high risk, on the basis of their 4Ts scores. The kappa statistic for inter-rater reliability of the 4Ts scores was 0.65 (95% CI: 0.50-0.80).
The AUC for the HIT-CR score as compared with a 4Ts score ≥ 4 was 0.91 (95% CI 0.86-0.97), and the stratumspecific likelihood ratios are shown in Table 3 Twelve patients in our study group underwent anti-PF4/H ELISA testing for HIT. Seven were tested despite having low-risk 4Ts scores, and all had a negative anti-PF4/H ELISA result. Our HIT-CR score logic would have recommended against HIT testing in six of the seven patients. Five patients with intermediate or high risk (4Ts score of ≥ 4) were appropriately tested. The HIT-CR score logic would have recommended testing in four of these five patients. The first of these five patients was diagnosed with HIT on the basis of a high-risk 4Ts score and a positive anti-PF4/H ELISA result. The second received argatroban for HIT, on the basis of clinical judgement, with an intermediate 4Ts score, a moderately high ELISA result (odds ratio of 1.405), and an indeterminate serotonin release assay result. The other three patients had negative anti-PF4/H ELISA results, including the patient for whom the HIT-CR score did not endorse diagnostic testing.
Fifty of the 150 patients in our study had clinical and laboratory data consistent with a 4Ts score of ≥ 4, but only five of these underwent recommended laboratory testing for HIT. Diagnostic testing would have been recommended by the HIT-CR score logic in 40 of the remaining 45 patients. Among these patients, 30 had persistent thrombocytopenia until discharge or death, and 17 did not have a clear alternative cause for thrombocytopenia besides HIT. Two patients with persistent thrombocytopenia developed thrombotic complications: one had bilateral lower-extremity ischemia resulting from an occlusive aortic thrombus, and the other experienced a fatal stroke. The HIT-CR score would have recommended HIT diagnostic testing in 16 of the 17 patients with persistent unexplained thrombocytopenia, including the two patients with thromboembolic events.
Discussion
The HIT-CR score (≥ 3) has good discriminant accuracy in determining whether a patient should undergo HIT diagnostic testing (i.e. 4Ts score of ≥ 4), and there is substantial agreement between the HIT-CR and 4Ts scores on the basis of the kappa statistic [16] . These operating characteristics support our decision to perform further clinical studies on the HIT-CR score to determine the impact on clinical outcomes after implementing the score into CDS as a screening tool to alert providers to test for potential cases of HIT.
Previous attempts to apply CDS to the diagnosis and management of HIT in patients receiving heparin have achieved mixed results. Riggio et al. implemented pop-up alerts for patients who had a 50% decrease in platelet counts or a 30% decrease if the absolute value was < 150 000 mm À3 [17] . The alert increased laboratory testing but failed to improve detection of HIT, yielding a positive predictive value of only 2.3%. Similarly, another study utilizing pop-ups alerted providers when platelet counts decreased by either 50% or were < 100 000 mm À3 , and resulted in increased diagnostic testing and the use of alternative anticoagulants, but failed to increase the rate (7) SD, standard deviation. at which HIT was diagnosed [18] . Neither of these studies compared their HIT CDS systems with a validated pretest risk score such as the 4Ts score. An additional study using CDS to identify patients with a 50% platelet count drop showed that only 38% of the patients identified by the alert had an intermediate or high 4Ts score [19] . All three of these studies utilized CDS systems that evaluated only the magnitude of thrombocytopenia without considering the timing of platelet count fall. It is our opinion that adding logic regarding the timing of onset of thrombocytopenia to the CDS system should improve the positive predictive value of an alert because benign, nonimmune-mediated thrombocytopenia is common early in the course of heparin and would be expected to degrade the specificity of an alert that fails to assess timing. However, differences in study design between our study and these previous studies preclude direct statistical comparisons.
Our study provides new data suggesting that clinicians may often fail to suspect HIT when there is considerable risk to their patients. To our knowledge, no previous study has reported the results of 4Ts scores and clinical outcomes in patients in whom there was no apparent clinical suspicion of HIT. Our study shows that only five of 50 (10%) patients with a 4Ts score of ≥ 4 underwent diagnostic testing for HIT, as is commonly recommended. Over a 7-week period in our healthcare system, 17 of those patients experienced unremitting and otherwise unexplained, thrombocytopenia, associated in two cases with severe thrombotic complications -one of which was fatal. These data support the hypothesis that the diagnosis of HIT is missed by clinicians, sometimes with life-threatening consequences, and provide a further rationale for implementation of effective HIT surveillance.
Extrapolation of our findings can provide some insights regarding the current state of clinical diagnosis of HIT in our healthcare system, and an estimate of how an operational CDS tool based on the HIT-CR score might affect diagnostic testing for HIT in the future. In 2017, about 87 000 patients received heparin or LMWH in our healthcare system. Thus, we might expect that 0.2% of patients, or about 174 patients, would have been diagnosed with HIT, but only 12 patients were assigned an ICD-10 diagnosis of HIT [3] . In 2017, 1034 patients underwent anti-PF4/H ELISA testing for HIT, reflecting a pretest probability for HIT of only 1.1% among tested patients. This 1.1% diagnosis rate is probably low because of ICD-10 coding issues, but these data are consistent with previous studies showing that as many as 84% of patients who undergo ELISA testing for HIT have a 4Ts score of ≤ 3 [20, 21] . As these patients have a pretest probability of < 2% for HIT [11] , few true-positive test results occur.
On the basis of the characteristics of the patients who are tested, and the findings of our present study, we suspect that current clinical decision-making regarding HIT has a high potential for two types of error: (i) testing patients who should not be tested (patients with a 4Ts score of ≤ 3); and (ii) failing to test patients who should be tested (those with a 4Ts score of ≥ 4). Extrapolation of our data suggests that full implementation of a CDS HIT alert, triggered by an HIT-CR score of ≥ 3, would identify about 1150 patients per year in our healthcare system with a 4Ts score ≥ 4. If all diagnostic testing for HIT was focused on these patients, the volume of ELISAs ordered would not dramatically change. However, errors in selecting the correct patients to test would decrease, and the number of patients diagnosed with HIT would increase. Appropriate testing of patients with an HIT-CR score of ≥ 3 has the potential to prevent severe and fatal thrombotic complications of undiagnosed HIT such as those potentially identified in our review of cases.
This pilot study has several limitations. Our use of disproportionate stratified sampling reduced our ability to calculate generalizable positive and negative predictive values for HIT-CR scores, and may have introduced spectrum bias that could have increased sensitivity and decreased specificity (as compared with an unselected group of hospitalized patients). This contention is based on the stratified likelihood ratios in Table 3 and on the distribution of HIT-CR scores observed in the general population that we studied, in which 92% of patients had a maximum HIT-CR score of 0. Owing to the lack of diagnostic testing being performed on patients in our sample, we compared the HIT-CR score with a widely used pretest risk score rather than a true reference standard such as HIT diagnosis. Also, this study included all inpatients receiving heparin or enoxaparin, and certain populations such as surgical or oncology patients might have different characteristics that could impact on the sensitivity and specificity of HIT-CR scoring within a particular subgroup, although our analysis of the kappa values in various subgroups did not show any major differences.
We plan to further develop and evaluate the HIT-CR score. We plan to implement a fully automated HIT-CR CDS system that can interact with clinicians to assist them in recognizing, diagnosing and treating HIT. Future studies will also evaluate the function of the HIT-CR score in specific populations such as patients undergoing cardiac surgery.
Conclusion
An automated HIT risk identification tool based on the first two components of the 4Ts score (thrombocytopenia and timing) demonstrates substantial agreement with the 4Ts score, and yields reasonable discriminant accuracy for identifying patients who are candidates for laboratory testing and further evaluation of HIT.
